{"nct_id": "NCT05592886", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Other: Active placebo"}, {"drug_name": "Other: SMT04 formula"}]}, "long_title": "A Double Blinded Randomized Controlled Trial of a Novel Oral Synbiotic Formula in Reducing Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "NA", "principal_investigator": "", "principal_investigator_institution": "Chinese University of Hong Kong", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 246, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "* 1. Subjects have advanced colorectal neoplasia requiring endoscopic resection (endoscopic mucosal resection, endoscopic submucosal dissection, etc.);", "* They have received high quality colonoscopies before or during endoscopic resection (defined as a full colonoscopy with successful caecal intubation, and a Boston Bowel Preparation Scale \u22672 in each colonic segment);", "* Aged 18-90 years old;", "* Written informed consent obtained", "Exclude - Exclusion Criteria:", "Exclude - * Known residual colorectal neoplasia not removed (except hyperplastic polyps);", "Exclude - * Contraindications to endoscopic resection due to deep submucosal invasion;", "Exclude - * Prior surgical resection of colon;", "Exclude - * Personal history of hereditary polyposis syndrome or inflammatory bowel disease;", "Exclude - * Known pregnancy or lactation;", "Exclude - * Immunocompromised status (e.g. on immunosuppressants (except 5-aminosalicylic acid or short term use of corticosteroids \\<4 weeks), on chemotherapy, bone marrow or solid organ transplant, human immunodeficiency virus, congenital immune deficiency);", "Exclude - * Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);", "Exclude - * Refusal to undergo surveillance colonoscopy."], "short_title": "A Novel Oral Synbiotic Formula in Reducing Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Chinese University of Hong Kong", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "This double blinded randomized controlled trial aims to assess the efficacy of a novel oral synbiotic formula (SMT04) in reducing adenoma recurrence and colorectal neoplasia-related bacterial gene markers after endoscopic resection of colorectal advanced neoplasia.", "treatment_list": {"step": [{"arm": [{"arm_code": "Intervention arm", "arm_internal_id": 0, "arm_description": "Receive SMT04 formula", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Other: SMT04 formula", "level_internal_id": 0, "level_suspended": "N"}]}, {"arm_code": "Placebo arm", "arm_internal_id": 1, "arm_description": "Receive active placebo", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Other: Active placebo", "level_internal_id": 0, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}